Given that cancer cells generally overexpress DR4 and DR546–49 and that, for a reason that still needs to be defined, signal transduction of apoptosis induced by these receptors appears to be fairly selective for tumour cells1,8,50, targeting TRAIL agonist receptors remains an interesting strategy in current anticancer drug development51. The gene discussed is TNFRSF10A; the disease is cancer.